Key result
Warfarin is linked to lower urinary gamma-carboxyglutamic acid excretion, which inversely correlates with prothrombin time.
Why the study?
The relationship between urinary gamma-carboxyglutamic acid excretion and coagulation status in warfarin-anticoagulated patients was investigated.
Does stable warfarin anticoagulant therapy reduce urinary excretion of gamma-carboxyglutamic acid (Gla) compared to normal controls?
Cross-Sectional (n=19)
Does stable warfarin anticoagulant therapy reduce urinary excretion of gamma-carboxyglutamic acid (Gla) compared to normal controls?
p-value: p=0.001
Urinary gamma-carboxyglutamic acid excretion is significantly reduced in patients on warfarin and correlates with prothrombin time, suggesting its potential as a clinical parameter for coagulation status.
Supports urinary Gla excretion as potential warfarin effect marker; leaves open clinical utility pending prospective validation.
The urinary excretion of gamma-carboxyglutamic acid (Gla), the amino acid involved in the vitamin K-dependent calcium binding of prothrombin and clotting factors VII, IX, and X, was studied in warfarin-anticoagulated patients. An isotope dilution procedure was developed for the measurement of free urinary Gla with the use of prior anion-exchange chromatography to separate and concentrate the free Gla from whole urine and subsequent automated amino acid analysis. Eight subjects on stable warfarin anticoagulant therapy and 11 comparable control subjects with normal coagulation were examined. Urinary Gla excretion was reduced in patients on warfarin anticoagulant therapy (p = 0.001) and the urinary Gla level correlated (r = -0.73, p = 0.001) with plasma prothrombin time. It is concluded that decreased urinary Gla in warfarin-treated patients is related to coagulation status and may be a clinically useful parameter.
No takes yet. Share an insight, caveat, or question.
Levy et al. (1979) conducted a cross-sectional in Warfarin anticoagulation (n=19). Warfarin therapy vs. Comparable control subjects with normal coagulation was evaluated on Urinary gamma-carboxyglutamic acid (Gla) excretion (p=0.001). Warfarin therapy was associated with reduced urinary gamma-carboxyglutamic acid excretion (p=0.001), which inversely correlated with plasma prothrombin time (r=-0.73, p=0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: